PDSB — PDS Biotechnology Corporation

Is PDSB overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

PDS Biotechnology Corporation (PDSB) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.92. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

PDS Biotechnology Corporation is a small, clinical-stage company whose valuation is highly dependent on near-term clinical and financing events. The company faces material execution and financing risk, limited revenue visibility, and a market environment favoring large-cap, defensive healthcare names. Absent clear non‑dilutive capital or positive clinical readouts, downside risk is elevated in the coming weeks.

Key factors

  • Clinical-stage biotech with binary, event-driven value tied to trial readouts and partnership activity.
  • Likely limited near-term revenue generation; value largely dependent on pipeline progress and external financing.
  • Small‑cap/low‑liquidity profile increases price volatility and sensitivity to news flow and sector sentiment.
  • Sector headwinds favor large-cap pharma and defensive healthcare, reducing investor appetite for early-stage biotechs.
  • Convertible-debt and financing environment risks increase probability of dilution for mid/small-cap biotech issuers.
  • Potential upside catalysts include positive clinical data, strategic partnerships or non-dilutive financing.

Risks

  • Clinical trial failure or disappointing data leading to sharp share-price declines.
  • Significant dilution from equity or convertible financings to fund operations.
  • Regulatory delays or negative interactions with regulators that push out milestones.
  • Competitive pressure from larger, better-capitalized companies in similar therapeutic areas.
  • Low analyst coverage and absence of strong social/research sentiment to support a recovery.
  • Macro/market risk: risk-off days and rotation into large-cap pharma could compress valuation further.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for PDSB — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.